Health Care Technology
Company Overview of Schrödinger, LLC
Schrödinger, LLC provides scientific software solutions and services for life sciences and materials research, as well as academic, government, and non-profit institutions around the world. It offers small-molecule drug discovery, biologics, materials science, and discovery informatics solutions; and PyMOL, a 3D molecular visualization solution. The company was founded in 1990 and is based in Portland, Oregon with operations in the United States, Europe, Japan, and India.
101 S.W. Main Street
Portland, OR 97204
Founded in 1990
Key Executives for Schrödinger, LLC
Co-Founder and Chief Financial Officer
Vice President and General Counsel
Managing Director and Senior Vice President
Senior Vice President of Strategy
Compensation as of Fiscal Year 2015.
Schrödinger, LLC Key Developments
Schrödinger, Inc. Announces Research Collaboration with Pfizer Inc
Jan 11 16
Schrödinger Inc. announced that it has entered into a research collaboration agreement with Pfizer Inc., in which the two companies will work together to develop a computational model for predicting key properties relevant to biotherapeutic candidates. In this collaboration, each company will perform tasks in an attempt to develop a novel model for predictions of properties. Pfizer will generate and provide experimental data against which the computational model is to be developed by the Schrödinger team, while teams from both companies will work together to determine future systems of interest to which to apply, test, and further refine the developing technology.
Schrodinger Signs Drug Discovery Collaboration with Sanofi
Apr 7 15
Schrodinger signed a multi-year early drug discovery collaboration with Sanofi. Under the contract, Schrodinger will offer target analysis and validation to lead identification and lead optimisation for around ten drug discovery programmes. Schrodinger is to receive up to USD 120 million, which includes preclinical milestones. A new enterprise informatics system will also facilitate real-time collaboration between computational designers and medicinal chemists and will serve as the communications and project management platform for researchers across both firms.
Sanofi Signs $120 million Collaboration Agreement with Schrodinger
Apr 2 15
Sanofi announced it has entered into a collaboration agreement with Schrodinger. Under the agreement, Schrodinger will provide comprehensive computational drug design support for as many as ten drug discovery programs. In return, Sanofi will pay up to $120 million, including pre-clinical milestones.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 15, 2015